MRNA
Price
$60.20
Change
-$0.87 (-1.42%)
Updated
Oct 4 closing price
26 days until earnings call
NTLA
Price
$17.65
Change
-$0.00 (-0.00%)
Updated
Oct 3 closing price
27 days until earnings call
Ad is loading...

MRNA vs NTLA

Header iconMRNA vs NTLA Comparison
Open Charts MRNA vs NTLABanner chart's image
Moderna
Price$60.20
Change-$0.87 (-1.42%)
Volume$6.22M
CapitalizationN/A
Intellia Therapeutics
Price$17.65
Change-$0.00 (-0.00%)
Volume$2.01M
CapitalizationN/A
View a ticker or compare two or three
MRNA vs NTLA Comparison Chart
Loading...
MRNA
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
NTLA
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
VS
MRNA vs. NTLA commentary
Oct 05, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is MRNA is a StrongBuy and NTLA is a Buy.

COMPARISON
Comparison
Oct 05, 2024
Stock price -- (MRNA: $60.20 vs. NTLA: $17.65)
Brand notoriety: MRNA: Notable vs. NTLA: Not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: MRNA: 116% vs. NTLA: 150%
Market capitalization -- MRNA: $25.27B vs. NTLA: $2.13B
MRNA [@Biotechnology] is valued at $25.27B. NTLA’s [@Biotechnology] market capitalization is $2.13B. The market cap for tickers in the [@Biotechnology] industry ranges from $531.34B to $0. The average market capitalization across the [@Biotechnology] industry is $2.87B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

MRNA’s FA Score shows that 1 FA rating(s) are green whileNTLA’s FA Score has 0 green FA rating(s).

  • MRNA’s FA Score: 1 green, 4 red.
  • NTLA’s FA Score: 0 green, 5 red.
According to our system of comparison, MRNA is a better buy in the long-term than NTLA.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

MRNA’s TA Score shows that 3 TA indicator(s) are bullish while NTLA’s TA Score has 4 bullish TA indicator(s).

  • MRNA’s TA Score: 3 bullish, 4 bearish.
  • NTLA’s TA Score: 4 bullish, 4 bearish.
According to our system of comparison, NTLA is a better buy in the short-term than MRNA.

Price Growth

MRNA (@Biotechnology) experienced а -8.44% price change this week, while NTLA (@Biotechnology) price change was -14.20% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +1.46%. For the same industry, the average monthly price growth was +1.89%, and the average quarterly price growth was -5.77%.

Reported Earning Dates

MRNA is expected to report earnings on Oct 31, 2024.

NTLA is expected to report earnings on Oct 31, 2024.

Industries' Descriptions

@Biotechnology (+1.46% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
MRNA($25.3B) has a higher market cap than NTLA($2.13B). MRNA YTD gains are higher at: -39.467 vs. NTLA (-42.112). NTLA has higher annual earnings (EBITDA): -514.18M vs. MRNA (-3.78B). MRNA has more cash in the bank: 8.49B vs. NTLA (691M). NTLA has less debt than MRNA: NTLA (106M) vs MRNA (1.27B). MRNA has higher revenues than NTLA: MRNA (4.99B) vs NTLA (46M).
MRNANTLAMRNA / NTLA
Capitalization25.3B2.13B1,186%
EBITDA-3.78B-514.18M734%
Gain YTD-39.467-42.11294%
P/E RatioN/AN/A-
Revenue4.99B46M10,843%
Total Cash8.49B691M1,228%
Total Debt1.27B106M1,197%
FUNDAMENTALS RATINGS
MRNA vs NTLA: Fundamental Ratings
MRNA
NTLA
OUTLOOK RATING
1..100
5357
VALUATION
overvalued / fair valued / undervalued
1..100
66
Overvalued
42
Fair valued
PROFIT vs RISK RATING
1..100
8596
SMR RATING
1..100
9696
PRICE GROWTH RATING
1..100
6585
P/E GROWTH RATING
1..100
2100
SEASONALITY SCORE
1..100
5050

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

NTLA's Valuation (42) in the Biotechnology industry is in the same range as MRNA (66). This means that NTLA’s stock grew similarly to MRNA’s over the last 12 months.

MRNA's Profit vs Risk Rating (85) in the Biotechnology industry is in the same range as NTLA (96). This means that MRNA’s stock grew similarly to NTLA’s over the last 12 months.

MRNA's SMR Rating (96) in the Biotechnology industry is in the same range as NTLA (96). This means that MRNA’s stock grew similarly to NTLA’s over the last 12 months.

MRNA's Price Growth Rating (65) in the Biotechnology industry is in the same range as NTLA (85). This means that MRNA’s stock grew similarly to NTLA’s over the last 12 months.

MRNA's P/E Growth Rating (2) in the Biotechnology industry is significantly better than the same rating for NTLA (100). This means that MRNA’s stock grew significantly faster than NTLA’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
MRNANTLA
RSI
ODDS (%)
Bullish Trend 2 days ago
70%
Bullish Trend 2 days ago
84%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
83%
Bullish Trend 2 days ago
77%
Momentum
ODDS (%)
Bearish Trend 2 days ago
78%
Bearish Trend 2 days ago
83%
MACD
ODDS (%)
N/A
Bearish Trend 2 days ago
84%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
82%
Bearish Trend 2 days ago
85%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
81%
Bearish Trend 2 days ago
88%
Advances
ODDS (%)
Bullish Trend 5 days ago
81%
Bullish Trend 22 days ago
78%
Declines
ODDS (%)
Bearish Trend 2 days ago
82%
Bearish Trend 2 days ago
85%
BollingerBands
ODDS (%)
N/A
Bullish Trend 2 days ago
89%
Aroon
ODDS (%)
Bearish Trend 2 days ago
78%
Bearish Trend 2 days ago
90%
View a ticker or compare two or three
Ad is loading...
MRNA
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
NTLA
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
ATRO19.980.66
+3.42%
Astronics Corp
AMH38.340.24
+0.63%
American Homes 4 Rent
PULM2.100.01
+0.48%
Pulmatrix
LRN80.17-1.90
-2.32%
Stride
CNTX1.92-0.06
-3.03%
Context Therapeutics

NTLA and

Correlation & Price change

A.I.dvisor indicates that over the last year, NTLA has been closely correlated with EDIT. These tickers have moved in lockstep 75% of the time. This A.I.-generated data suggests there is a high statistical probability that if NTLA jumps, then EDIT could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To NTLA
1D Price
Change %
NTLA100%
-4.85%
EDIT - NTLA
75%
Closely correlated
-0.62%
BEAM - NTLA
75%
Closely correlated
-2.38%
CRSP - NTLA
72%
Closely correlated
-1.77%
VCYT - NTLA
69%
Closely correlated
-2.44%
PRME - NTLA
67%
Closely correlated
-0.58%
More